Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn. Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
View Top Employees from Dynavax TechnologiesWebsite | http://www.dynavax.com |
Ticker | DVAX |
Revenue | $8 million |
Funding | $293.9 million |
Employees | 363 (363 on RocketReach) |
Founded | 1996 |
Address | 2100 Powell St Suite 900, Emeryville, California 94608, US |
Phone | (510) 848-5100 |
Fax | (510) 848-1327 |
Technologies |
JavaScript,
HTML,
Google Analytics
+52 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Biotechnology, Health Care, Science and Engineering, Clinical Trials, Medical Device |
Web Rank | 1 Million |
Keywords | Vaccine Development, Infectious Disease, Biopharmaceuticals, Research And Development, Clinical Trials, Regulatory Affairs |
Competitors | Genocea, Immatics, Omeros Corporation, Otonomy, Inc, Sorrento Therapeutics, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies, NAICS Code 32 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Dynavax Technologies employee's phone or email?
The Dynavax Technologies annual revenue was $8 million in 2024.
David Novack is the President and Chief Operating Officer of Dynavax Technologies.
363 people are employed at Dynavax Technologies.
Dynavax Technologies is based in Emeryville, California.
The NAICS codes for Dynavax Technologies are [541, 54171, 541714, 32, 5417, 54, 325, 3254].
The SIC codes for Dynavax Technologies are [283, 28].